SPYRE THERAPEUTICS
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies with the potential to revolutionize the treatment of inflammatory bowel disease (IBD).
SPYRE THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.spyretx.com
Total Employee:
51+
Status:
Active
Total Funding:
360 M USD
Technology used in webpage:
Domain Not Resolving SPF Amazon Microsoft Exchange Online Office 365 Mail GoDaddy DNS Amazon S3 CDN DMARC Slack Apple ICloud Mail
Stock Details
Investors List
RTW Investments
RTW Investments investment in Post-IPO Equity - Spyre Therapeutics
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Spyre Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Spyre Therapeutics
Farallon Capital Management
Farallon Capital Management investment in Post-IPO Equity - Spyre Therapeutics
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Spyre Therapeutics
Darwin Global
Darwin Global investment in Post-IPO Equity - Spyre Therapeutics
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Spyre Therapeutics
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Spyre Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Spyre Therapeutics
Polar Capital
Polar Capital investment in Post-IPO Equity - Spyre Therapeutics
Official Site Inspections
http://www.spyretx.com
- Host name: 147.75.40.150
- IP address: 147.75.40.150
- Location: Amsterdam Netherlands
- Latitude: 52.2832
- Longitude: 4.7521
- Timezone: Europe/Amsterdam
- Postal: 1119
More informations about "Spyre Therapeutics"
Spyre Therapeutics
Engineering for new heights in the treatment of Inflammatory Bowel Disease. Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and …See details»
Aeglea BioTherapeutics Announces Acquisition of Spyre …
Jun 22, 2023 Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) …See details»
Spyre Therapeutics, Inc. | Investor Relations - Company Overview
Nov 12, 2024 The structure, code and organization of this Website are proprietary to us. This Website contains material, including but not limited to software, text, graphics and images …See details»
Aeglea BioTherapeutics Announces Acquisition of Spyre …
Jun 22, 2023 Management and Organization. The current Aeglea management team, including Jonathan D. Alspaugh, President & Chief Financial Offer, ... Visit Spyre's website at …See details»
Aeglea BioTherapeutics Announces Name Change to Spyre …
Nov 27, 2023 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre …See details»
Aeglea BioTherapeutics Announces Grant of Inducement Awards
Jun 23, 2023 Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the …See details»
Spyre Therapeutics, Inc. | Investor Relations - Press Releases
WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today …See details»
Spyre Therapeutics - Crunchbase Company Profile & Funding
Spyre Therapeutics reported its financial results for the fourth quarter and full year 2023, as well as the first quarter of 2024. The company provided corporate updates in both reports.See details»
Aeglea BioTherapeutics Announces Name Change to Spyre …
Nov 27, 2023 Follow Spyre Therapeutics on social media: @spyretx and LinkedIn Forward-Looking Statements Certain statements in this press release, other than purely historical …See details»
Aeglea BioTherapeutics Announces Grant of Inducement Awards
Jun 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....See details»
Our Approach | Spyre Therapeutics
*JNJ VEGA Study, Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023)See details»
Aeglea BioTherapeutics Announces Acquisition of Spyre …
Jun 22, 2023 Visit Spyre’s website at www.spyretx.com. Follow Spyre Therapeutics on social media: @spyretx and LinkedIn. About Paragon Therapeutics. Paragon Therapeutics, Inc. is a …See details»
Join Us | Spyre Therapeutics
We are a collaborative interdisciplinary team, united in our drive to innovate and dedicated to enhancing patient lives. If you’re passionate about making a tangible difference and thrive in a …See details»
Spyre Therapeutics, Inc. | Investor Relations - Press Releases
Jun 22, 2023 Follow Spyre Therapeutics on social media: @spyretx and LinkedIn About Paragon Therapeutics Paragon Therapeutics, Inc. is a biotechnology company leveraging …See details»
Aeglea BioTherapeutics Announces Acquisition of Spyre …
Jun 22, 2023 Management and Organization. The current Aeglea management team, including Jonathan D. Alspaugh, ... Follow Spyre Therapeutics on social media: @spyretx and LinkedIn.See details»
Pipeline | Spyre Therapeutics
Our co-lead product candidate, SPY003, is designed to be a highly potent, selective, and half-life extended monoclonal antibody that binds to the p19 subunit of interleukin-23 cytokine (“IL …See details»
Aeglea BioTherapeutics Announces Name Change to Spyre …
Nov 27, 2023 Follow Spyre Therapeutics on social media: @spyretx and LinkedIn. Forward-Looking Statements Certain statements in this press release, other than purely historical …See details»
Chief Executive Officer - Spyre
Cameron Turtle, DPhil, is Chief Executive Officer. He is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage …See details»
SVP, Chief Intellectual Property Counsel - Spyre
Fehlner assisted the World Health Organization in design of the COVID-19 Technology Access Pool (C-TAP) in 2020-21, presented at the 2019 Brocher Foundation expert working group on …See details»
Chief Financial Officer - Spyre
Scott Burrows, M.B.A., is Chief Financial Officer. He is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track-record in biopharmaceutical …See details»